Cyclic depsipeptides as potential cancer therapeutics

Area of Science:

• Biochemistry
• Pharmacology
• Medicinal Chemistry

Background:

• Cyclic depsipeptides are natural products containing ester bonds, derived from amino acids and hydroxy acids.
• These compounds exhibit diverse biological activities, including antitumor, antifungal, and antiviral properties.
• Natural cyclic depsipeptides are sourced from fungi, plants, and marine organisms.

Purpose of the Study:

• To review antitumor cyclic depsipeptides that have advanced to clinical trials.
• To analyze their structural characteristics, mechanisms of action, and therapeutic applications in cancer chemotherapy.
• To summarize pharmacokinetic and toxicity data for these agents.

Main Methods:

• Literature review of clinical trials involving antitumor cyclic depsipeptides.
• Analysis of published data on structural features, biological mechanisms, and clinical efficacy.
• Compilation of pharmacokinetic and toxicity profiles from preclinical and clinical studies.

Main Results:

• Romidepsin (FK228), a bicyclic depsipeptide, inhibits histone deacetylase and is approved for refractory cutaneous T-cell lymphoma.
• Several cyclic depsipeptides have demonstrated potent effects on tumor cells, leading to clinical investigations.
• Despite mixed trial outcomes, romidepsin's success validates the therapeutic potential of this compound class.

Conclusions:

• Antitumor cyclic depsipeptides represent a promising source for novel cancer therapeutics.
• Further research into their structural optimization and clinical application is warranted.
• These compounds hold significant potential for development into effective chemotherapeutic agents.